Bristol-Myers Squibb/$BMY
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
- Ticker
- $BMY
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 32,500
- Headquarters
- Princeton, United States
- Website
- www.bms.com
BMY Metrics
BasicAdvanced
$136B
14.66
$4.54
0.23
$2.51
3.78%
Price and volume
Market cap
$136B
Beta
0.23
52-week high
$68.64
52-week low
$42.52
Average daily volume
11M
Dividend rate
$2.51
Financial strength
Current ratio
1.532
Quick ratio
1.29
Long term debt to equity
196.33
Total debt to equity
201.859
Dividend payout ratio (TTM)
54.89%
Interest coverage (TTM)
9.08%
Profitability
EBITDA (TTM)
18,930
Gross margin (TTM)
71.66%
Net profit margin (TTM)
18.87%
Operating margin (TTM)
31.79%
Effective tax rate (TTM)
22.12%
Revenue per employee (TTM)
$1,510,000
Management effectiveness
Return on assets (TTM)
10.72%
Return on equity (TTM)
46.60%
Valuation
Price to earnings (TTM)
14.656
Price to revenue (TTM)
2.758
Price to book
6.09
Price to tangible book (TTM)
-8.09
Price to free cash flow (TTM)
11.858
Free cash flow yield (TTM)
8.43%
Free cash flow per share (TTM)
5.615
Dividend yield (TTM)
3.77%
Forward dividend yield
3.78%
Growth
Revenue change (TTM)
3.11%
Earnings per share change (TTM)
82.74%
3-year revenue growth (CAGR)
2.87%
10-year revenue growth (CAGR)
10.81%
3-year earnings per share growth (CAGR)
6.51%
10-year earnings per share growth (CAGR)
10.27%
3-year dividend per share growth (CAGR)
3.71%
10-year dividend per share growth (CAGR)
5.21%
What the Analysts think about BMY
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
BMY Financial Performance
Revenues and expenses
BMY Earnings Performance
Company profitability
BMY News
AllArticlesVideos
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Business Wire2 days ago
Bristol Myers ends blood cancer drug deal with cell therapy maker Cellares
Reuters6 days ago
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.